3 ms·
No, this was entirely intentional on behalf of the FDA. They wanted to move unapproved products out of the dark and move them through a formal approval process
by refurb 5y ago
No, this was entirely intentional on behalf of the FDA. They wanted to move unapproved products out of the dark and move them through a formal approval process.
As a part of that process, they offered market exclusivity as an incentive for a company to spend the time and money to do so. As I said in another response, the filing fee alone is $1.6M. It's not as expensive as a full NDA approval, but it's not free.
And your article lays it all out.
"Their study used Medicaid and Medicare data files through 2017, when combined Medicaid and Medicare claims exceeded $340 million for colchicine.
"Colcrys's manufacturer, which conducted a 1-week trial (n=185), received 3 years' market exclusivity for treatment of acute gout, and the unapproved formulations were soon ordered off the market, resulting in a virtual monopoly," McCormick's group noted."
So the price goes up for 3 years and as a result you get a fully FDA approved drug? Not worth that trade off?
- cityzen 5y agoWe can agree to disagree. I do not think it's worth it at all.